West Pharmaceutical Services (WST) Stock Forecast, Price Target & Predictions
WST Stock Forecast
West Pharmaceutical Services stock forecast is as follows: an average price target of $345.33 (represents a 12.41% upside from WST’s last price of $307.21) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
WST Price Target
The average price target for West Pharmaceutical Services (WST) is $345.33 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $536.00 to $250.00. This represents a potential 12.41% upside from WST's last price of $307.21.
WST Analyst Ratings
According to 7 Wall Street analysts, West Pharmaceutical Services's rating consensus is 'Buy'. The analyst rating breakdown for WST stock is 0 'Strong Buy' (0.00%), 5 'Buy' (71.43%), 2 'Hold' (28.57%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
West Pharmaceutical Services Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Feb 07, 2024 | David Windley | Jefferies | $536.00 | $413.00 | 29.78% | 74.47% |
| Dec 14, 2022 | - | Deutsche Bank | $250.00 | $251.90 | -0.75% | -18.62% |
| Nov 30, 2022 | - | UBS | $250.00 | $222.84 | 12.19% | -18.62% |
The latest West Pharmaceutical Services stock forecast, released on Feb 07, 2024 by David Windley from Jefferies, set a price target of $536.00, which represents a 29.78% increase from the stock price at the time of the forecast ($413.00), and a 74.47% increase from WST last price ($307.21).
West Pharmaceutical Services Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $536.00 |
| Last Closing Price | $307.21 | $307.21 | $307.21 |
| Upside/Downside | -100.00% | -100.00% | 74.47% |
In the current month, the average price target of West Pharmaceutical Services stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to West Pharmaceutical Services's last price of $307.21. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Feb 15, 2024 | William Blair | Outperform | Outperform | Hold |
| Feb 07, 2024 | Jefferies | - | Buy | Upgrade |
| Jun 16, 2023 | Morgan Stanley | - | Buy | Upgrade |
| Jun 16, 2023 | Bank of America Securities | - | Buy | Upgrade |
| Apr 11, 2023 | Stephens | Overweight | Positive | Upgrade |
| Apr 11, 2023 | Stephens | - | Overweight | Upgrade |
| Feb 16, 2023 | William Blair | Outperform | Outperform | Hold |
| Dec 14, 2022 | Deutsche Bank | - | Hold | Initialise |
| Nov 30, 2022 | UBS | - | Neutral | Initialise |
West Pharmaceutical Services's last stock rating was published by William Blair on Feb 15, 2024. The company gave WST a "Outperform" rating, the same as its previous rate.
West Pharmaceutical Services Financial Forecast
West Pharmaceutical Services Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $732.00M | $747.40M | $753.80M | $716.60M | $708.70M | $686.90M | $771.30M | $720.00M | $730.80M | $706.50M | $723.60M | $670.70M | $580.20M | $548.00M | $527.20M | $491.50M | $470.60M | $456.10M |
| Avg Forecast | $851.81M | $832.12M | $842.89M | $804.70M | $796.38M | $781.32M | $757.43M | $732.21M | $739.97M | $709.62M | $729.36M | $670.62M | $739.46M | $750.31M | $755.71M | $698.19M | $657.17M | $727.42M | $754.25M | $720.92M | $710.20M | $687.09M | $669.38M | $603.99M | $540.37M | $502.72M | $496.09M | $466.79M | $451.54M | $450.76M |
| High Forecast | $866.66M | $846.62M | $857.58M | $818.72M | $810.25M | $794.93M | $770.63M | $734.36M | $757.92M | $709.78M | $729.36M | $670.62M | $741.36M | $756.26M | $768.88M | $710.36M | $668.62M | $727.42M | $754.25M | $720.92M | $710.20M | $687.09M | $669.38M | $603.99M | $540.37M | $502.72M | $496.09M | $466.79M | $451.54M | $450.76M |
| Low Forecast | $841.08M | $821.63M | $832.27M | $794.56M | $786.34M | $771.47M | $747.88M | $730.05M | $727.62M | $709.46M | $729.36M | $670.62M | $737.76M | $741.00M | $746.19M | $689.39M | $648.88M | $727.42M | $754.25M | $720.92M | $710.20M | $687.09M | $669.38M | $603.99M | $540.37M | $502.72M | $496.09M | $466.79M | $451.54M | $450.76M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 4 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 9 | 9 | 9 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | 1.00% | 1.00% | 1.03% | 1.08% | 0.94% | 1.02% | 1.00% | 1.03% | 1.03% | 1.08% | 1.11% | 1.07% | 1.09% | 1.06% | 1.05% | 1.04% | 1.01% |
West Pharmaceutical Services's average Quarter revenue forecast for Mar 24 based on 4 analysts is $670.62M, with a low forecast of $670.62M, and a high forecast of $670.62M. WST's average Quarter revenue forecast represents a -8.38% decrease compared to the company's last Quarter revenue of $732.00M (Dec 23).
West Pharmaceutical Services EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 4 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 9 | 9 | 9 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $214.00M | $218.60M | $182.50M | $186.90M | $129.70M | $168.90M | $257.10M | $216.50M | $218.90M | $219.40M | $250.30M | $210.90M | $149.40M | $133.90M | $135.40M | $117.30M | $108.80M | $94.60M |
| Avg Forecast | $234.39M | $228.98M | $231.94M | $221.43M | $219.14M | $215.00M | $208.42M | $201.48M | $203.62M | $195.27M | $200.70M | $251.13M | $203.48M | $206.46M | $207.95M | $228.30M | $225.74M | $198.06M | $205.36M | $207.54M | $193.37M | $187.08M | $182.25M | $131.41M | $147.13M | $136.88M | $135.07M | $90.12M | $122.94M | $122.73M |
| High Forecast | $238.48M | $232.97M | $235.98M | $225.29M | $222.96M | $218.74M | $212.05M | $202.07M | $208.56M | $195.31M | $200.70M | $301.35M | $204.00M | $208.10M | $211.57M | $273.96M | $270.89M | $198.06M | $205.36M | $249.05M | $193.37M | $187.08M | $182.25M | $157.69M | $147.13M | $136.88M | $135.07M | $108.14M | $122.94M | $122.73M |
| Low Forecast | $231.44M | $226.09M | $229.02M | $218.64M | $216.38M | $212.29M | $205.79M | $200.89M | $200.22M | $195.22M | $200.70M | $200.90M | $203.01M | $203.90M | $205.33M | $182.64M | $180.59M | $198.06M | $205.36M | $166.03M | $193.37M | $187.08M | $182.25M | $105.13M | $147.13M | $136.88M | $135.07M | $72.10M | $122.94M | $122.73M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 1.06% | 0.88% | 0.82% | 0.57% | 0.85% | 1.25% | 1.04% | 1.13% | 1.17% | 1.37% | 1.60% | 1.02% | 0.98% | 1.00% | 1.30% | 0.88% | 0.77% |
4 analysts predict WST's average Quarter EBITDA for Mar 24 to be $251.13M, with a high of $301.35M and a low of $200.90M. This is 17.35% upper than West Pharmaceutical Services's previous annual EBITDA (Dec 23) of $214.00M.
West Pharmaceutical Services Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 4 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 9 | 9 | 9 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $137.00M | $161.30M | $155.10M | $140.00M | $103.00M | $120.60M | $188.50M | $173.80M | $147.70M | $175.60M | $187.30M | $151.20M | $98.40M | $82.30M | $91.20M | $74.30M | $63.90M | $56.30M |
| Avg Forecast | $169.59M | $164.12M | $163.64M | $151.64M | $152.66M | $144.45M | $134.20M | $123.48M | $125.78M | $110.15M | $127.80M | $192.44M | $130.52M | $136.28M | $141.40M | $174.95M | $152.32M | $156.24M | $162.69M | $159.04M | $141.17M | $132.41M | $128.22M | $94.21M | $82.91M | $73.26M | $66.88M | $57.08M | $53.15M | $52.18M |
| High Forecast | $173.43M | $167.84M | $167.35M | $155.07M | $156.11M | $147.73M | $137.23M | $124.25M | $134.22M | $111.65M | $127.81M | $230.93M | $136.39M | $142.14M | $144.60M | $209.94M | $182.78M | $156.24M | $162.69M | $190.85M | $142.06M | $132.41M | $128.22M | $113.05M | $82.91M | $73.26M | $66.88M | $68.50M | $53.15M | $52.18M |
| Low Forecast | $166.81M | $161.43M | $160.96M | $149.15M | $150.16M | $142.09M | $132.00M | $122.72M | $120.86M | $108.66M | $127.80M | $153.95M | $126.85M | $131.88M | $139.08M | $139.96M | $121.85M | $156.24M | $162.69M | $127.23M | $140.29M | $132.41M | $128.22M | $75.37M | $82.91M | $73.26M | $66.88M | $45.67M | $53.15M | $52.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 1.18% | 1.10% | 0.80% | 0.68% | 0.77% | 1.16% | 1.09% | 1.05% | 1.33% | 1.46% | 1.60% | 1.19% | 1.12% | 1.36% | 1.30% | 1.20% | 1.08% |
West Pharmaceutical Services's average Quarter net income forecast for Mar 24 is $192.44M, with a range of $153.95M to $230.93M. WST's average Quarter net income forecast represents a 40.47% increase compared to the company's last Quarter net income of $137.00M (Dec 23).
West Pharmaceutical Services SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 4 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 9 | 9 | 9 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $90.00M | $89.00M | $88.40M | $86.00M | $85.70M | $66.30M | $81.50M | $83.40M | $98.00M | $91.90M | $92.70M | $80.20M | $76.30M | $76.20M | $77.70M | $71.80M | $69.00M | $64.80M |
| Avg Forecast | $110.15M | $107.61M | $109.00M | $104.06M | $102.98M | $101.04M | $97.95M | $94.69M | $95.69M | $91.77M | $94.32M | $92.35M | $95.62M | $97.03M | $97.73M | $83.95M | $101.06M | $94.07M | $97.54M | $76.32M | $91.84M | $88.85M | $86.56M | $49.97M | $69.88M | $65.01M | $64.15M | $55.16M | $58.39M | $58.29M |
| High Forecast | $112.07M | $109.48M | $110.90M | $105.87M | $104.78M | $102.80M | $99.65M | $94.97M | $98.01M | $91.79M | $94.32M | $110.81M | $95.87M | $97.80M | $99.43M | $100.74M | $121.28M | $94.07M | $97.54M | $91.58M | $91.84M | $88.85M | $86.56M | $59.96M | $69.88M | $65.01M | $64.15M | $66.20M | $58.39M | $58.29M |
| Low Forecast | $108.77M | $106.25M | $107.63M | $102.75M | $101.69M | $99.76M | $96.71M | $94.41M | $94.09M | $91.74M | $94.32M | $73.88M | $95.40M | $95.82M | $96.49M | $67.16M | $80.85M | $94.07M | $97.54M | $61.06M | $91.84M | $88.85M | $86.56M | $39.98M | $69.88M | $65.01M | $64.15M | $44.13M | $58.39M | $58.29M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.94% | 0.92% | 0.90% | 1.02% | 0.85% | 0.70% | 0.84% | 1.09% | 1.07% | 1.03% | 1.07% | 1.60% | 1.09% | 1.17% | 1.21% | 1.30% | 1.18% | 1.11% |
West Pharmaceutical Services's average Quarter SG&A projection for Mar 24 is $92.35M, based on 4 Wall Street analysts, with a range of $73.88M to $110.81M. The forecast indicates a 2.61% rise compared to WST last annual SG&A of $90.00M (Dec 23).
West Pharmaceutical Services EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 4 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 9 | 9 | 9 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.17 | $2.09 | $1.88 | $1.38 | $1.62 | $2.53 | $2.34 | $1.98 | $2.37 | $2.53 | $2.04 | $1.33 | $1.11 | $1.24 | $1.01 | $0.86 | $0.76 |
| Avg Forecast | $2.31 | $2.24 | $2.23 | $2.07 | $2.08 | $1.97 | $1.83 | $1.68 | $1.71 | $1.50 | $1.74 | $1.27 | $1.78 | $1.86 | $1.93 | $1.67 | $1.38 | $2.12 | $2.21 | $2.12 | $1.92 | $1.80 | $1.74 | $1.43 | $1.12 | $0.99 | $0.91 | $0.82 | $0.72 | $0.71 |
| High Forecast | $2.36 | $2.29 | $2.28 | $2.11 | $2.13 | $2.01 | $1.87 | $1.69 | $1.83 | $1.52 | $1.74 | $1.27 | $1.86 | $1.94 | $1.97 | $1.71 | $1.41 | $2.12 | $2.21 | $2.12 | $1.93 | $1.80 | $1.74 | $1.43 | $1.12 | $0.99 | $0.91 | $0.82 | $0.72 | $0.71 |
| Low Forecast | $2.27 | $2.20 | $2.19 | $2.03 | $2.05 | $1.94 | $1.80 | $1.67 | $1.65 | $1.48 | $1.74 | $1.27 | $1.73 | $1.80 | $1.89 | $1.64 | $1.35 | $2.12 | $2.21 | $2.12 | $1.90 | $1.80 | $1.74 | $1.43 | $1.12 | $0.99 | $0.91 | $0.82 | $0.72 | $0.71 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.17% | 1.08% | 1.13% | 1.00% | 0.76% | 1.15% | 1.10% | 1.03% | 1.32% | 1.45% | 1.43% | 1.18% | 1.12% | 1.37% | 1.23% | 1.19% | 1.07% |
According to 5 Wall Street analysts, West Pharmaceutical Services's projected average Quarter EPS for Dec 23 is $1.78, with a low estimate of $1.73 and a high estimate of $1.86. This represents a -18.06% decrease compared to WST previous annual EPS of $2.17 (Sep 23).
West Pharmaceutical Services Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| COO | Cooper Companies | $99.48 | $298.00 | 199.56% | Buy |
| BAX | Baxter | $33.02 | $60.38 | 82.86% | Hold |
| RGEN | Repligen | $123.41 | $193.86 | 57.09% | Buy |
| TFX | Teleflex | $194.43 | $304.36 | 56.54% | Buy |
| BDX | Becton, Dickinson and Company | $224.10 | $283.27 | 26.40% | Buy |
| HAE | Haemonetics | $88.17 | $108.25 | 22.77% | Buy |
| WST | West Pharmaceutical Services | $307.21 | $345.33 | 12.41% | Buy |
| ALC | Alcon | $85.81 | $93.89 | 9.42% | Buy |
| HOLX | Hologic | $78.79 | $80.21 | 1.80% | Buy |
| ICUI | ICU Medical | $169.98 | $172.00 | 1.19% | Buy |
| MMSI | Merit Medical Systems | $103.94 | $100.78 | -3.04% | Buy |
| RMD | ResMed | $239.42 | $219.13 | -8.47% | Hold |
| EMBC | Embecta | $14.42 | $12.00 | -16.78% | Sell |